Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Triple Negative Invasive Lobular Carcinoma”

10 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 10 of 10 results

Testing effectiveness (Phase 2)Looking for participantsNCT07229417
What this trial is testing

A Trial Evaluating the Efficacy of Ivonescimab in Metastatic Endocrine Refractory HR-positive HER2-negative or Triple Negative Invasive Lobular Carcinoma

Who this might be right for
Metastatic Endocrine RefractoryTriple Negative Invasive Lobular Carcinoma
M.D. Anderson Cancer Center 29
Large-scale testing (Phase 3)Study completedNCT02620280
What this trial is testing

Neoadjuvant Therapy in TRIPle Negative Breast Cancer With antiPDL1

Who this might be right for
Invasive Ductal Breast Carcinoma
Fondazione Michelangelo 278
Testing effectiveness (Phase 2)Ended earlyNCT03979508
What this trial is testing

Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer

Who this might be right for
Anatomic Stage I Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8+15 more
Mayo Clinic 26
Testing effectiveness (Phase 2)Study completedNCT01849250
What this trial is testing

Study of Docosahexaenoic Acid (DHA) in Triple Negative Breast Cancer Survivors

Who this might be right for
Benign Breast NeoplasmDuctal Breast Carcinoma In SituInvasive Breast Carcinoma+9 more
National Cancer Institute (NCI) 65
Testing effectiveness (Phase 2)Looking for participantsNCT05269381
What this trial is testing

Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors

Who this might be right for
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IIIA Breast Cancer AJCC v8Anatomic Stage IIIB Breast Cancer AJCC v8+98 more
Mayo Clinic 138
Large-scale testing (Phase 3)Study completedNCT01426880
What this trial is testing

Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer

Who this might be right for
Tubular Breast Cancer Stage IIMucinous Breast Cancer Stage IIBreast Cancer Female NOS+5 more
GBG Forschungs GmbH 595
Not applicableLooking for participantsNCT04959474
What this trial is testing

Pre-operative SABR With and Without Caloric Restriction for Early Stage Breast Cancer

Who this might be right for
Anatomic Stage 0 Breast Cancer AJCC v8Anatomic Stage 1 Breast Cancer AJCC v8Anatomic Stage 2 Breast Cancer AJCC v8+4 more
Thomas Jefferson University 80
Large-scale testing (Phase 3)Active Not RecruitingNCT02221999
What this trial is testing

Weekly Paclitaxel and Cisplatin to Treat Hormone Receptor Positive and Triple Negative Breast Cancer Patients

Who this might be right for
Tubular Breast CancerMucinous Breast CancerInvasive Ductal Breast Cancer+1 more
RenJi Hospital 250
Post-approval studies (Phase 4)Looking for participantsNCT04790305
What this trial is testing

Effect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast Cancer

Who this might be right for
Carcinoma BreastTriple-negative Breast CancerInvasive Ductal Carcinoma, Breast
Fudan University 1,072
Testing effectiveness (Phase 2)Study completedNCT02779855
What this trial is testing

Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer

Who this might be right for
Breast CancerDuctal CarcinomaInvasive Breast Carcinoma+1 more
H. Lee Moffitt Cancer Center and Research Institute 50